Baxter licensing of Innocoll gentamicin implant
Baxter will have exclusive rights in the U.S. to market and distribute Innocoll's gentamicin surgical implant - a biodegradable, leave-behind antibiotic surgical sponge used as an add-on therapy for prevention and treatment of surgical site infections. The product will be regulated as a drug and will be reviewed by CDER, according to the firm. Under the terms of its licensing agreement with Innocoll, Baxter will pay a licensing fee and will make contingent clinical, regulatory and commercial milestone payments; Innocoll will manufacture and supply product, as well as shepherding Gentamicin through the regulatory process. The product is already approved for use in other parts of the world
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.